Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus
César López-Camacho 1,†
, Young Chan Kim 1,2,†, Joshua Blight 1,3, Marcos Lazaro Moreli 1,4, Eduardo Montoya-Diaz 1,5, Juha T Huiskonen 2, Beate Mareike Kümmerer 6 and Arturo Reyes-Sandoval 1,*
, Young Chan Kim 1,2,†, Joshua Blight 1,3, Marcos Lazaro Moreli 1,4, Eduardo Montoya-Diaz 1,5, Juha T Huiskonen 2, Beate Mareike Kümmerer 6 and Arturo Reyes-Sandoval 1,*
1
The Jenner Institute, Nuffield Department of Medicine, University of Oxford. The Henry Wellcome Building for Molecular Physiology, Roosevelt Drive, Oxford, OX3 7BN, UK
2
Division of Structural Biology, University of Oxford, Wellcome Centre for Human Genetics, Roosevelt Drive, Headington, Oxford, OX3 7BN, UK
3
Department of Life Sciences, Imperial College London, Sir Alexander Fleming Building, Exhibition Road, South Kensington, London, SW7 2AZ, UK
4
Virology Laboratory, Federal University of Goiás, Jataí 75801615, Brazil
5
Veterinary Medicine Division, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, 63225, Germany
6
Institute of Virology, University of Bonn Medical Centre, Bonn 53127, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this manuscript
Viruses 2019, 11(4), 322; https://doi.org/10.3390/v11040322
Received: 1 March 2019 / Revised: 25 March 2019 / Accepted: 29 March 2019 / Published: 3 April 2019
(This article belongs to the Special Issue Chikungunya Virus and (Re-) Emerging Alphaviruses)
Abstract
Chikungunya virus (CHIKV) has caused extensive outbreaks in several countries within the Americas, Asia, Oceanic/Pacific Islands, and Europe. In humans, CHIKV infections cause a debilitating disease with acute febrile illness and long-term polyarthralgia. Acute and chronic symptoms impose a major economic burden to health systems and contribute to poverty in affected countries. An efficacious vaccine would be an important step towards decreasing the disease burden caused by CHIKV infection. Despite no licensed vaccine is yet available for CHIKV, there is strong evidence of effective asymptomatic viral clearance due to neutralising antibodies against the viral structural proteins. We have designed viral-vectored vaccines to express the structural proteins of CHIKV, using the replication-deficient chimpanzee adenoviral platform, ChAdOx1. Expression of the CHIKV antigens results in the formation of chikungunya virus-like particles. Our vaccines induce high frequencies of anti-chikungunya specific T-cell responses as well as high titres of anti-CHIKV E2 antibodies with high capacity for in vitro neutralisation. Our results indicate the potential for further clinical development of the ChAdOx1 vaccine platform in CHIKV vaccinology. View Full-TextKeywords:
chikungunya virus; CHIKV; ChAdOx1; viral-vectored vaccines; immunogenicity
▼
Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
López-Camacho, C.; Kim, Y.C.; Blight, J.; Lazaro Moreli, M.; Montoya-Diaz, E.; T Huiskonen, J.; Mareike Kümmerer, B.; Reyes-Sandoval, A. Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus. Viruses 2019, 11, 322.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.